Annales pharmaceutiques francaises最新文献

{"title":"[Training pharmacy students to conduct targeted interviews on oral anticoagulants: Development and evaluation of training using healthcare simulation].","authors":"Léa Jamart, Justine Clarenne, Florian Slimano, Dominique Hettler, Pauline Quillet","doi":"10.1016/j.pharma.2024.09.001","DOIUrl":"10.1016/j.pharma.2024.09.001","url":null,"abstract":"<p><strong>Objectives: </strong>Pharmaceutical care for patients receiving oral anticoagulants (OACs) should be performed by trained healthcare professionals to prevent adverse effects and improve patient adherence. Before meeting patients, all pharmacy students in our department (in a one-year hospital internship program) experienced a theoretical training for several years. It was decided to add a practical component based on simulation training. The study reports the simulation program conception and the assessment of the simulation-based training for pharmacy students involved in conducting interviews with patients receiving ACOs.</p><p><strong>Methods: </strong>Organization and content of the training course were defined by two hospital pharmacists and one pharmacy resident. Skills' assessment was measured in pharmacy students in 3 steps: (1) initial assessment by individual interview, (2) group training by simulation, (3) final assessment by individual interview. Student satisfaction was also assessed at the end of the training.</p><p><strong>Results: </strong>Four scenarios and one assessment form were developed and 16 pharmacy students experienced the training. An improvement in skills after the simulations courses was observed in all parts of the process: the pre-interview (mean +15%), the interview itself (+16%) and the post-interview (+18%). All students felt more comfortable and motivated to conduct interviews and recommended that this training be continued.</p><p><strong>Conclusions: </strong>The study underlines the impact of the simulation training on students' skills and their satisfaction with the overall training program. The simulation training is now fully added to the program. Further studies should explore the skills improvement in real life during the first patient interview.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Role of cranioplasty in the management of decompressive craniectomies: Study of the Adolphe de Rothschild Foundation Hospital cohort over 7 years].","authors":"Zohra Gachouch, Georges Nicolaos, Claire Judel, Chloé Dupont, Caroline Le Guerinel","doi":"10.1016/j.pharma.2024.09.004","DOIUrl":"https://doi.org/10.1016/j.pharma.2024.09.004","url":null,"abstract":"<p><strong>Objectives: </strong>The objective of our study is to take stock of the cranioplasty implants used within our establishment.</p><p><strong>Materials and method: </strong>We analyzed the patients files who underwent craniectomy followed by cranioplasty between 2017 and 2023, with at least 1 year of follow-up after cranioplasty (n=75). The data were extracted from the computerized patient file (DxCare®, Dédalus) and the pharmaceutical management tool for drugs and sterile medical devices (Pharma®, Computer Engineering). The sex ratio, indication for craniectomy, operating time, time between craniectomy and cranioplasty, complications and aesthetic result were statistically analyzed.</p><p><strong>Results: </strong>The main indications are stroke (n=59; 78.5%) and aneurysms (n=7; 9.5%). Among the 75 patients, 52 benefited from the placement of a custom implant (PolyEtherEtherCetone/PEEK or Hydroxyapatite) and 23 from cementoplasty. The operating time was significantly shorter (P<0.05) for custom cranioplasty (1.93±0.61h vs. 1.62±0.53). Only 4 patients (5.3%) were not satisfied with the aesthetic result following the placement of a custom implant. A greater risk of infection was found in the context of cementoplasty (43% for cementoplasties vs. 25% for the custom implant, so χ² (P=0.1095), this difference not being statistically significant.</p><p><strong>Conclusion: </strong>This collaborative work between the pharmacy and the adult neurosurgery department served to establish an initial register for monitoring patients who have undergone cranioplasty for whom the ideal implant remains to be determined.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Lipoprotein-associated phospholipase A₂ (Lp-PLA₂): Relevant biomarker and therapeutic target?]","authors":"Dominique Bonnefont-Rousselot","doi":"10.1016/j.pharma.2024.08.011","DOIUrl":"10.1016/j.pharma.2024.08.011","url":null,"abstract":"<p><p>Over the last fifteen years, numerous studies have sought to decipher the role of lipoprotein-associated phospholipase A₂ (Lp-PLA₂) in vascular inflammation-related diseases, notably atherosclerosis. Despite the disappointing results of clinical trials using the Lp-PLA₂ inhibitor darapladib, new pathophysiological, epidemiological and genetic data have enabled the development of new inhibitors. Recent studies also show that Lp-PLA₂ is involved in vascular inflammation-related diseases other than atherosclerosis (ischemic stroke, Alzheimer's disease and vascular dementia, diabetes, cancers…), and inhibition of Lp-PLA₂ could have beneficial therapeutic in these diseases. This review aims to present new data on Lp-PLA₂ and to evaluate its current interest as a biomarker but also as a therapeutic target.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development, optimization and validation of an analytical method for the determination of voriconazole in plasma by high-performance liquid chromatography-ultraviolet detection: Application for comprehensive study","authors":"","doi":"10.1016/j.pharma.2024.05.002","DOIUrl":"10.1016/j.pharma.2024.05.002","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;p&gt;Voriconazole is a widely used antifungal agent in clinical settings. However, its use has been associated with neurological side effects in some patients. For this reason, it is crucial to monitor its plasma levels to ensure that they are within the therapeutic range. Thus, in this study, we aimed to develop a simple, fast, and efficient method for the determination of voriconazole in plasma using reversed-phase HPLC-UV. We also aimed to validate the method for its application to routine analysis of immunocompromised patients.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Material and methods&lt;/h3&gt;&lt;p&gt;Plasma samples from immunocompromised patients were subjected to deproteinization with acetonitrile followed by centrifugation. Chromatographic separation was carried out on a C18 column with UV detection at 254&lt;!--&gt; &lt;!--&gt;nm in isocratic mode. The concentrations were calculated by comparing peak areas to those of the internal standard, ketoconazole. The method was validated using the accuracy profile, which uses a calibration curve established for the therapeutic range of 1 to 5.5&lt;!--&gt; &lt;!--&gt;μg/mL.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;The developed method was proved to be rapid by giving a short analysis time for voriconazole at around 5.5&lt;!--&gt; &lt;!--&gt;min. Additionally, no interference with the biological matrix was detected. The obtained recoveries were higher than 90%. The accuracy profile showed that the method was accurate and precise for the determination of voriconazole in plasma.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;The developed method was proved to be simple, efficient, that requires minimal sample preparation. Thus, it can be routinely applied for the therapeutic monitoring of voriconazole.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;But/Objectif&lt;/h3&gt;&lt;p&gt;Le voriconazole est un antifongique largement utilisé en milieu clinique. Cependant, son utilisation est associée à des effets secondaires neurologiques chez certains patients. Il est donc essentiel de surveiller les concentrations plasmatiques pour s’assurer qu’elles se situent dans la fourchette thérapeutique. Dans cette étude, nous avons cherché à développer une méthode simple, rapide et efficace pour la détermination du voriconazole dans le plasma en utilisant la CLHP-UV en phase inversée. Nous avons également cherché à valider la méthode et à l’appliquer aux patients immunodéprimés.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Matériel et méthodes&lt;/h3&gt;&lt;p&gt;Les échantillons de plasma de patients immunodéprimés ont été soumis à une déprotéinisation avec de l’acétonitrile suivie d’une centrifugation. La séparation chromatographique a été effectuée sur une colonne C18 avec détection UV à 254&lt;!--&gt; &lt;!--&gt;nm en mode isocratique. Les concentrations ont été calculées en comparant les surfaces des pics à celles de l’étalon interne, le kétoconazole. La méthode a été validée à l’aide du profil d’exactitude, qui utilise une courbe d’étalonnage établie pour la gamme thérapeutique de 1 à 5,5&lt;!--&gt; &lt;!--&gt;μg/mL.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;p&gt;La méthode développée n","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140904036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A UPLC method development and validation study of Upadacitinib and its impurities in extended – release oral tablet dosage forms","authors":"","doi":"10.1016/j.pharma.2024.03.007","DOIUrl":"10.1016/j.pharma.2024.03.007","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;The primary objective was to develop a concomitant isocratic ultra-performance liquid chromatographic photo-diode array detection method to estimate Upadacitinib and its process-related impurities: impurity-1 and impurity-2. Further validation was conducted and studied for possible degradants under stress environments.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and methods&lt;/h3&gt;&lt;p&gt;All the chemicals and reagents used were of HPLC (acetonitrile, methanol) and analytical grade (trifluoro acetic acid). The ultra-performance liquid chromatography (Agilent 1290 Infinity II LC system) consists of a quaternary pump, a BEH C18 (50&lt;!--&gt; &lt;!--&gt;×&lt;!--&gt; &lt;!--&gt;2.1&lt;!--&gt; &lt;!--&gt;mm, 1.7&lt;!--&gt; &lt;!--&gt;μ) column, and photo-diode array detector. The method was developed with acetonitrile: methanol: 0.1% v/v trifluoro acetic acid (50:20:30 v/v/v) mobile phase at 0.2&lt;!--&gt; &lt;!--&gt;mL/min flow rate within a run time of 5.5&lt;!--&gt; &lt;!--&gt;min The detection was carried at 231.2&lt;!--&gt; &lt;!--&gt;nm.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;The respective retention times achieved were 2.289&lt;!--&gt; &lt;!--&gt;min (Upadacitinib), 0.972&lt;!--&gt; &lt;!--&gt;min (Upadacitinib impurity-1), and 3.508&lt;!--&gt; &lt;!--&gt;min (Upadacitinib impurity-2). The optimized method was validated further, and the linearity range was best fit at 15.0–180.0&lt;!--&gt; &lt;!--&gt;μg/mL for Upadacitinib and 1.0–12.0&lt;!--&gt; &lt;!--&gt;μg/mL for both Upadacitinib impurity-1 and 2 respectively. The detection and quantification limits were 4.50&lt;!--&gt; &lt;!--&gt;μg/mL, 15.00&lt;!--&gt; &lt;!--&gt;μg/mL (Upadacitinib) and 0.30&lt;!--&gt; &lt;!--&gt;μg/mL, 1.0&lt;!--&gt; &lt;!--&gt;μg/mL (Upadacitinib impurity-1 and 2).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;A fast, isocratic, specific, and reproducible ultra-performance liquid chromatographic method was developed and validated for various parameters according to the ICH Q2 (R1) guidelines studies. Stress studies were conducted exposing the sample dilution to various treatments (acid, alkali, peroxide, HPLC water, heat, and UV light). The degradants were well-separated apart from the peaks of the active substance. The stability indicating nature was observed during the degradation. The optimized method can be applied for the separation and estimation of Upadacitinib and its process-related impurities in pharma sector in tablet dosage forms.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;p&gt;L’objectif principal était de développer une méthode de détection concomitante par chromatographie liquide ultra-performante par réseau de photodiodes isocratiques pour estimer l’Upadacitinib et ses impuretés liées au processus: impureté-1 et impureté-2. Une validation plus approfondie a été menée et étudiée pour d’éventuels dégradants dans des conditions de stress.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Matériels et méthodes&lt;/h3&gt;&lt;p&gt;Tous les produits chimiques et réactifs utilisés étaient de qualité HPLC (acétonitrile, méthanol) et analytique (acide trifluoroacétique). La chromatographie liquide ultra-performante (système LC Agilent 1290 Infinity II) se compose d’une pompe quaternaire, d’une colonne BEH C18 (50&lt;!--&gt; &lt;","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140329586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sommaire / Contents","authors":"","doi":"10.1016/S0003-4509(24)00119-6","DOIUrl":"10.1016/S0003-4509(24)00119-6","url":null,"abstract":"","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0003450924001196/pdfft?md5=45772e68f90fff82ada25f1c6a19a5fd&pid=1-s2.0-S0003450924001196-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142099341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of engineered transferosomal gel containing meloxicam for the treatment of osteoarthritis","authors":"","doi":"10.1016/j.pharma.2024.04.006","DOIUrl":"10.1016/j.pharma.2024.04.006","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;.In this study, we investigated the potential of meloxicam (MLX) developed as transferosomal gel as a novel lipidic drug delivery system to address osteoarthritis (OTA), a degenerative joint disease that causes pain and stiffness. By incorporating meloxicam into a transferosomal gel, our aim was to provide a targeted and efficient delivery system capable of alleviating symptoms and slowing down the progression of OTA.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Material and methods&lt;/h3&gt;&lt;p&gt;Classical lipid film hydration technique was utilized to formulate different transferosomal formulations. Different transferosomal formulations were prepared by varying the molar ratio of phospholipon-90H (phosphodylcholine) to DSPE (50:50, 60:40, 70:30, 80:20, and 90:10) and per batch, 80&lt;!--&gt; &lt;!--&gt;mg of total lipid was used. The quality control parameters such as entrapment efficiency, particle size and morphology, polydispersity and surface electric charge, in vitro drug release, ex vivo permeation and stability were measured.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;The optimized transferosomal formulations revealed a small vesicle size (121&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;12&lt;!--&gt; &lt;!--&gt;nm) and greater MLX entrapment (68.98&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;2.3%). Transferosomes mediated gel formulation MLX34 displayed pH (6.3&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;0.2), viscosity (6236&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;12.3 cps), spreadability (13.77&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;1.77 gm.cm/sec) and also displayed sustained release pattern of drug release (81.76&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;7.87% MLX released from Carbopol-934 gel matrix in 24&lt;!--&gt; &lt;!--&gt;h). MLX34 revealed close to substantial anti-inflammatory response, with ∼81% inhibition of TNF-α in 48&lt;!--&gt; &lt;!--&gt;h. Physical stability analysis concluded that refrigerator temperature was the preferred temperature to store transferosomal gel.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;MLX loaded transferosomes containing gel improved the skin penetration and therefore resulted into increased inhibition of TNF-α level.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;p&gt;Dans cette étude, nous avons étudié le potentiel du méloxicam (MLX) développé sous forme de gel transférosomal en tant que nouveau système d'administration de médicaments lipidiques pour traiter l'arthrose (OTA), une maladie articulaire dégénérative qui provoque des douleurs et des raideurs. En incorporant du méloxicam dans un gel transférosomal, notre objectif était de fournir un système d'administration ciblé et efficace capable de soulager les symptômes et de ralentir la progression de l'OTA.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Matériel et méthodes&lt;/h3&gt;&lt;p&gt;La technique classique d’hydratation du film lipidique a été utilisée pour formuler différentes formulations transférosomales. Différentes formulations transférosomiques ont été préparées en faisant varier le rapport molaire du phospholipon-90H (phosphodylcholine) au DSPE (50:50, 60:40, 70:30, 80:20 et 90:10) et par lot, 80&lt;!--&gt; &lt;!--&gt;mg de lipides totaux a été utilisé. Les paramètres de contrôle qualité ","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140777599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exavir : mise en place et évaluation de l’acquisition de compétences en pharmacologie expérimentale par des étudiants en pharmacie","authors":"","doi":"10.1016/j.pharma.2024.03.008","DOIUrl":"10.1016/j.pharma.2024.03.008","url":null,"abstract":"<div><p>Avec l’évolution de la réglementation européenne et française de l’expérimentation animale dans l’enseignement supérieur, prenant davantage en compte le bien-être animal, l’université d’Angers a développé un logiciel d’expérimentation animale virtuelle : Exavir. Utilisé pour les travaux pratiques (TP) de physiologie, de pharmacologie et de toxicologie en cursus Santé, sciences et à l’IUT, Exavir offre la possibilité de simuler différentes expériences à visée pédagogique in vivo ou ex vivo. Grâce à un fonctionnement original intégrant des jeux sérieux avec différents scenarii, les étudiants gagnent en autonomie et deviennent directement acteurs de leur apprentissage. De plus, par un développement collaboratif et participatif, Exavir favorise les partenariats interuniversitaires et l’émergence de pédagogies innovantes. Une étude pilote hybride basée sur un échantillon de 22 étudiants réalisée au département pharmacie de la faculté de santé indique qu’Exavir permet d’améliorer l’acquisition de compétences pédagogiques tant dans le domaine de la physiologie que de la pharmacologie, par les étudiants en comparaison à des TP d’expérimentation uniquement sur organes animaux. Ces résultats encourageants démontrent pour la première fois les avantages pédagogiques d’Exavir et confirment l’intérêt de développer une telle plateforme. Dans ce contexte, il apparaît qu’Exavir ouvre également la possibilité d’adapter les TP proposés au sein des universités et ainsi répondre à l’évolution des questions éthiques des prochaines décennies.</p></div><div><p>With the evolution of European and French regulations on animal experimentation in higher education, taking greater account of animal welfare, the University of Angers has developed a virtual animal experimentation software named Exavir. Used for practical work (PW) in physiology, pharmacology and toxicology in the Health, Sciences, and engineering curricula, Exavir can be used to simulate various experiments for teaching purposes, in vivo or ex vivo. Thanks to an original approach integrating serious games with different scenarios, students gain autonomy and become directly involved in their learning. In addition, Exavir's collaborative and participative development approach fosters inter-university partnerships and the emergence of innovative teaching methods. A hybrid pilot study carried out on a sample of 22 students in the Pharmacy Department of the Faculty of Health showed that Exavir improved students’ acquisition of teaching skills in both physiology and pharmacology, compared with practical work only based on animal organs. These encouraging results demonstrate for the first time the pedagogical advantages of Exavir and confirm the interest in developing such a platform. In this context, it appears that Exavir also opens up the possibility of adapting the practical work offered within universities, and thus responding to the changing ethical issues of the coming decades.</p></div>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140783869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Connaissances et pratiques des étapes préalables à la stérilisation des dispositifs médicaux thermorésistants : étude au centre hospitalo-universitaire Sahloul, Sousse-Tunisie – 2022","authors":"","doi":"10.1016/j.pharma.2024.04.003","DOIUrl":"10.1016/j.pharma.2024.04.003","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objectifs&lt;/h3&gt;&lt;p&gt;La démarche ordinaire de la stérilisation centrale est primordiale pour le fonctionnement optimal du bloc opératoire. Le résultat de ce processus est étroitement lié aux étapes préalables à l’étape de stérilisation proprement dite. Ces étapes comprennent la pré-désinfection faite au niveau des blocs opératoires et les autres étapes à savoir le lavage, le séchage et le conditionnement qui doivent être réalisées au niveau de l’unité de stérilisation centrale. Dans cette logique ce travail a été mené pour décrire les connaissances du personnel des blocs opératoires et de l’unité de stérilisation centrale du centre hospitalo-universitaire Sahloul de Sousse (Tunisie) en 2022, sur les étapes préalables à la stérilisation des dispositifs médicaux réutilisables thermorésistants et décrire leurs pratiques en matière du respect de ces étapes.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthode&lt;/h3&gt;&lt;p&gt;Une étude descriptive a été menée du mois de janvier 2022 jusqu’au mois de juin 2022, auprès du personnel sus-cité, moyennant un questionnaire auto-administré pour étudier leurs connaissances sur les étapes préalables à la stérilisation et un audit par observation directe de leurs pratiques de ces étapes. Les deux instruments de mesure ont été pré-testés.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;p&gt;Sur 102 questionnaires auto-administrés (étude des connaissances) distribués aux personnels concernés, seulement 80 ont été rendus et remplis correctement, soit un taux de réponses de 78,4 %. Les réponses des participants concernant l’ordre des étapes préalables de la stérilisation ont été incorrectes dans 64 % des cas. Concernant l’évaluation des pratiques professionnelles, 224 observations ont été faites sur le terrain d’étude (audit des pratiques). Dans 82 % de ces observations, l’étape de la pré-désinfection a été confondue avec celle du lavage. L’utilisation des brosses bétadinées et des tampons à récurer pour le lavage des dispositifs a été noté dans 89,3 %, ainsi qu’une absence d’écouvillonnage des canaux et des parties creuses dans 9,4 % des cas et l’absence de séchage des canaux par l’air comprimé.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;La maîtrise des étapes préalables à la stérilisation des DMR était insuffisante dans notre établissement, ce qui suggère l’importance du renforcement de la mise en place de la procédure par un programme de formation continue suivi de plans d’actions.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;p&gt;The standard process of central sterilization is crucial for the optimal functioning of the operating room. The outcome of this process is closely linked to the steps preceding the steps prior to the sterilization step itself. These steps include pre-disinfection carried out in the operating rooms and other stages, namely washing, drying and packaging, which must be performed in the central sterilization unit. In this context, this study aimed to describe the knowledge of the staff in the operating rooms and the central sterilization unit at Sahloul Unive","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140785072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The harms of inappropriate digoxin prescribing in cancer patients: A drug-drug interaction with posaconazole","authors":"","doi":"10.1016/j.pharma.2024.04.005","DOIUrl":"10.1016/j.pharma.2024.04.005","url":null,"abstract":"","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140775575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}